Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

The researchers reported that a new nanoformulation of paclitaxel-loaded nanoparticles showed superior antitumor effects against malignant melanoma in vitro and in vivo compared to the commercial formulation Taxol^®.

In vitro, this study found that PTX and HU SF-FA NLCs showed greater cytotoxicity and apoptosis in ovarian cancer cells than pure paclitaxel, suggesting promise as a targeted drug delivery platform.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.

This review discusses various nanoparticles and nanoemulsions being investigated for transdermal drug delivery and reports no clinical results; it highlights potential applications in treating alopecia, wound healing, psoriasis, and melanoma.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study reports that a novel bioabsorbable nano-micelle hybridized hydrogel scaffold may reduce postoperative melanoma recurrence and mitigate the side effects of doxorubicin in mouse models.

This study found that oral paclitaxel combined with encequidar improved tumor response rates compared to intravenous paclitaxel in women with metastatic breast cancer, while also reducing neuropathy but increasing certain gastrointestinal and neutropenic side effects.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

This review examines the molecular mechanisms by which the proapoptotic protein ARTS inhibits tumorigenesis and discusses prospects for developing drugs that mimic its function, with no new experimental results reported.

This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This case series found that paclitaxel and nab-paclitaxel may be safe and effective chemotherapy options for hemodialysis patients with unresectable advanced or recurrent gastric cancer.

This review discusses nanoparticle-based topical delivery systems for treating skin diseases and presents no new clinical findings; it emphasizes natural polymer-based nanoparticles and future applications like targeted drug delivery.

This review discusses the role of phytochemical nanoparticles in cervical cancer therapy and reports no new clinical results; the authors highlight their potential advantages over conventional chemotherapy.

This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.

This review discusses the role of nanoparticles in cancer diagnosis and treatment and outlines their potential to improve outcomes by reducing systemic toxicity and overcoming multidrug resistance, though it reports no new clinical results.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

In this study, a newly engineered scaffold, PADM-MX-Ag-Si@Dox, demonstrated potential as a multifunctional biomaterial for postoperative melanoma treatment by controlling drug release, enhancing wound healing, and enabling real-time tumor surveillance through temperature, pH, and electrical stimuli.

This study reported that a novel nanomedicine combining berberine and sinapic acid significantly inhibited the growth of mouse mammary carcinoma cells and demonstrated an anti-tumor effect in vivo, without significant systemic toxicity after 28 days, suggesting a promising, low-toxicity therapeutic strategy for breast cancer.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.